This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jerrold G. Bernstein, MD
Human Resource Institute of Boston 227 Babcock St Brookline, MA 02146

JAMA. 1980;243(4):331-332.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Torsion dystonia (dystonia muscularum deformans) is a rare condition that is generally difficult to diagnose and more difficult to treat. Our limited understanding of this condition suggests that its mechanism involves abnormalities in one or more neurotransmitter substances in the basal ganglia of the brain.

Development of a variety of drugs that modify central neurotransmission has offered considerable therapeutic advance in the treatment of a variety of neurological and psychiatric conditions. Because of the rarity of torsion dystonia, few controlled studies of therapeutic agents have been accomplished in this condition. On the other hand, a variety of clinicians have had experience with one or more patients whose conditions responded or even worsened with one or another pharmacologic approach.

I am presently reviewing the pharmacologic treatment of this condition in an attempt to consolidate published and unpublished information regarding potential treatment and mechanisms involved in torsion dystonia. I . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?